Back to Results
First PageMeta Content
Health / Antibiotic resistance / Antibacterial / New Delhi metallo-beta-lactamase 1 / Carbapenem / Drug resistance / Rib-X Pharmaceuticals / Phage therapy / Antibiotics / Medicine / Biology


New Drugs 4 Bad Bugs (ND4BB) Topic 5 : Clinical Development of antibacterial agents for Gram-negative antibiotic resistant pathogens EFPIA partners : AstraZeneca, Basilea, Cubist, GSK Dr Seamus O’Brien AstraZeneca
Add to Reading List

Document Date: 2013-07-09 11:31:07

Open Document

File Size: 1,11 MB

Share Result on Facebook

City

Delhi / /

Company

AstraZeneca / PublicPrivate Partnership / /

Continent

Europe / /

Country

United Kingdom / /

Event

FDA Phase / /

MedicalCondition

infections / /

MedicalTreatment

Antibiotics / /

Organization

World Health Organization / G8 / MEDI4893 ND4BB Information Centre / /

Person

Justin Lindemann / J. Antimicrob Chemother / Lancet / /

Position

investigator / medical chief / /

Product

ND4BB / /

Technology

ATM / AVI / /

SocialTag